(secondQuint)Prediction of Everolimus-induced Interstitial Lung Disease.

 In this study the investigators will prospectively investigate pulmonary adverse events during treatment with everolimus.

 The investigators will distinguish the following everolimus-induced pulmonary adverse events: pulmonary infection, everolimus-induced airway disease and everolimus-induced interstitial lung disease (ILD).

 The investigators will investigate the predictive value of pneumoproteins, everolimus exposure, pulmonary function tests, four distinct radiological patterns, baseline patient characteristics and the development of skin toxicity or oral mucositis for the development and severity of everolimus-induced ILD.

.

 Prediction of Everolimus-induced Interstitial Lung Disease@highlight

The investigators will determine which factors are predictive for the development and severity of everolimus-induced interstitial lung disease and will develop a prediction model based on these risk factors.

